Declaration of interests VRA declares institutional contracts with Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept Therapeutics, Eli Lilly, Fractyl Health, Kailera, Novo Nordisk, Pfizer, Recordati, Rhythm Pharmaceuticals, and Servier; and consulting for Baim Institute for Clinical Research, Mediflix, Roche, and Sanofi. RB has received payment or honoraria for lectures, presentations, speakers bureaus, or educational events from Eli Lilly Italia, Sanofi, Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Abiogen, Guidotti, Theras, Dexcom, and Novartis; has received support for attending meetings or travel from Eli Lilly, Sanofi, Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Abiogen, Guidotti, Theras, Dexcom, and Novartis; has participated on an Advisory Board for Eli Lilly Italia, Sanofi, Abbott, Novo Nordisk, Dexcom, Bayer, and Daiichi; and is president of the Italian Society of Diabetes. S-MD, JHL, AV, and TW are employees of and shareholders in Novo Nordisk. ABJ has received clinical trials funding from Abbott, Amgen, Argenx, AstraZeneca, Eli Lilly, Novo Nordisk, Roche, and Sanofi Aventis; and has received speaking honorarium or advisory compensation from Abbott, AbbVie, AstraZeneca, Amgen, Antibody, Bausch Healthcare, Bayer, Boehringer Ingelheim, Celltrion, Dexcom, Diabetes Canada, Eli Lilly, Embecta, GSK, HLS Therapeutics, Insulet, Janssen, Kailera, Merck, Medtronic, Moderna, Novartis, Novo Nordisk, Pendopharm, Pfizer, Roche, Sandoz, Takeda, and Ypsomed. CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB BIO, vTv Therapeutics, and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Dexcom, Novo Nordisk, and Sanofi; CM serves or has served on the speakers’ bureau for Novo Nordisk, Sanofi, Eli Lilly, Medtronic, Dexcom, Insulet, Abbott, Vertex, and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is president of the European Diabetes Forum. All external support of the European Diabetes Forum is to be found on www.eudf.org. REP is supported by National Institutes of Health research grants U01DK106993, R01DK138060, U01DK35131, R01DK143524, U01DK143384, U01DK127392; has received investigator-initiated grant support (directed to his institution) from Abbott Laboratories, AstraZeneca, Biomea Fusion, Boehringer Ingelheim International, Carmot Therapeutics, Dompé, Eli Lilly, Endogenex, Fractyl Health, Lexicon Pharmaceuticals, Novo Nordisk, and Sanofi; has received consultancy fees from Abbott Laboratories, AbbVie, Altanine, Amgen, AstraZeneca Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Corcept Therapeutics, Crinetics Pharmaceuticals, Endogenex, F Hoffmann-La Roche, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Recordati Rare Diseases, Regeneron Pharmaceuticals, Response Pharmaceuticals, Rona Therapeutics, Scholar Rock, Sun Pharmaceutical Industries, Third Rock Ventures, and Verdiva Bio Dev; has received speaker fees from Corcept, Lilly USA, and Novo Nordisk; and has stock options in Altanine. JBB has received salary support from clinical trial contracts to his employer by Corcept, Dexcom, GentiBio, Novo Nordisk, and Sparrow Pharmaceuticals; has received salary support from consulting contracts to his employer by Novo Nordisk; is a consultant with personal compensation from Aardvark Therapeutics, Altimmune, Alveus Therapeutics, Amgen, Antag, Aqua Medical, AstraZeneca, Boehringer Ingelheim, Corcept Therapeutics, Dexcom, Eli Lilly, Embecta, General Medicines, GentiBio, Kayothera, Metsera, MiniMed, Pfizer, Recordati, Roche, Sparrow Pharmaceuticals, Vertex, vTv Therapeutics, and Zealand; and has stock options in Aardvark, Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health.
PubMed
